Restenosis - Pipeline Review, H2 2016

Date: August 24, 2016
Pages: 48
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: RC570BF72FAEN
Leaflet:

Download PDF Leaflet

Restenosis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Restenosis - Pipeline Review, H2 2016’, provides an overview of the Restenosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Restenosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Restenosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Restenosis
  • The report reviews pipeline therapeutics for Restenosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Restenosis therapeutics and enlists all their major and minor projects
  • The report assesses Restenosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Restenosis
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Restenosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Restenosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Restenosis Overview
Therapeutics Development
Pipeline Products for Restenosis - Overview
Pipeline Products for Restenosis - Comparative Analysis
Restenosis - Therapeutics under Development by Companies
Restenosis - Therapeutics under Investigation by Universities/Institutes
Restenosis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Restenosis - Products under Development by Companies
Restenosis - Products under Investigation by Universities/Institutes
Restenosis - Companies Involved in Therapeutics Development
Bio3 Research S.r.l
CytoTools AG
XBiotech Inc
Restenosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(connective tissue growth factor + insulin human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alendronate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Antagonize HMGB-1 for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CV-18C3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
didox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMW-02Ak - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMW-02Ap - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HO-3867 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TW-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Restenosis - Dormant Projects
Restenosis - Discontinued Products
Restenosis - Product Development Milestones
Featured News & Press Releases
Jan 03, 2013: XBiotech Receives Fast Track Designation From FDA For True Human Monoclonal Antibody Therapy Targeting Inflammatory Cytokine IL-1a For Restenosis
Nov 20, 2012: XBiotech Reports Positive Phase II Interim Analysis Results Of MABp1 In Vascular Disease
Aug 18, 2011: XBiotech Announces Initiation Of Restenosis Clinical Trial In All Five US Sites
Dec 22, 2010: XBiotech Files IND For CV-18C3 Monoclonal Antibody Therapy To Treat Peripheral Vascular Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Restenosis, H2 2016
Number of Products under Development for Restenosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Restenosis - Pipeline by Bio3 Research S.r.l, H2 2016
Restenosis - Pipeline by CytoTools AG, H2 2016
Restenosis - Pipeline by XBiotech Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Restenosis - Dormant Projects, H2 2016
Restenosis - Dormant Projects (Contd..1), H2 2016
Restenosis - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Restenosis, H2 2016
Number of Products under Development for Restenosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Restenosis - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 55 pages
Psoriasis - Pipeline Review, H1 2016 US$ 2,125.00 Apr, 2016 · 771 pages
Moderate Psoriasis - Pipeline Review, H1 2015 US$ 1,600.00 Apr, 2015 · 137 pages
Hidradenitis Suppurativa - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 63 pages

Ask Your Question

Restenosis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: